Aladdin Healthcare Technologies SE

  • WKN: A12ULL
  • ISIN: DE000A12ULL2
  • Land: Deutschland

Nachricht vom 26.03.2021 | 07:30

Aladdin Healthcare Technologies starts OTC Entry Level Listing in the USA and looks forward to further expansion

DGAP-News: Aladdin Healthcare Technologies SE / Key word(s): Miscellaneous
26.03.2021 / 07:30
The issuer is solely responsible for the content of this announcement.

Aladdin Healthcare Technologies starts OTC Entry Level Listing in the USA and looks forward to further expansion

BERLIN/LONDON, March 26, 2021 - Aladdin Healthcare Technologies SE ("Aladdin", ISIN: DE000A12ULL2), a leading developer of Artificial Intelligence (AI) based healthcare diagnostics and drug discovery applications, is pleased to announce the start of its listing on the OTC market. Aladdin's shares are now trading on the Pink Open Market (former: OTC Pink) under the stock symbol ALDNF.

The Pink Open Market is the entry level market operated by the OTC Markets Group and is intended only as starting point for Aladdin. From here, Aladdin intends to move to OTCQB or OTCQX this year once it meets specific criteria. In order to be upgraded to the higher tiers of OTC, companies have to meet stricter financial standards and demonstrate compliance with applicable securities laws.

With the US listing, Aladdin will improve the liquidity of its shares and increase the attractiveness and accessibility of the shares to the capital markets at a more international level.

Wade Menpes-Smith, CEO of Aladdin Healthcare Technologies, comments: "Our listing on the US stock market is an important and strategic step towards the successful implementation of our growth strategy. It enables our company to be more accessible to international investors and it increases the liquidity of our shares. We are looking forward to expanding our business worldwide."

Aladdin's shares will continue to trade on the Düsseldorf and the Frankfurt Stock Exchange.
 

About Aladdin Healthcare Technologies SE
Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a leading developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early stage disease diagnosis and the end-to-end drug discovery process. Aladdin targets age-related diseases including a significant focus on Alzheimer's disease. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to confidentially and securely gather targeted data including, genome, tabular, MRI, PET, cognition and other lifestyle data. These datasets are then analysed by our award-winning AI team and used to develop proprietary AI tools that can assist healthcare professionals to more accurately and efficiently diagnose age-related diseases. This new diagnostic process will save significant time and costs for healthcare professionals. Additionally, our AI drug discovery platform will be used by pharmaceutical Companies to speed up drug development, clinical trials and predict outcomes more accurately.

Website Link: www.aladdinid.com
GSIN: A12ULL
ISIN: DE000A12ULL2
TICKER SYMBOL: NMI

For further information:

Aladdin Healthcare Technologies Ltd.
24-26 Baltic Street West
London EC1Y 0UR
Phone +44 7714 719696
Email: info@aladdinid.com

Contact Press
CROSS ALLIANCE communication GmbH
Sara Pinto
Phone +49 89 1250 90330
Email: pi@crossalliance.de
www.crossalliance.de



26.03.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Event im Fokus

How to Vergütungsbericht?

Im Zulauf auf die neue Berichtssaison adressiert das hkp/// group Tutorial die wichtigsten Neuerungen für die Kommunikation von Vorstands- und Aufsichtsratsvergütung im Vergütungsbericht.

Mittwoch, 18. August 2021, 14:00 -15:30 Uhr

Event im Fokus

Termine 2021

10. Juni 2021:Fachkonferenz Immobilien

14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure

13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie

10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix

„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“

GBC-Fokusbox

Cryptology Asset Group PLC: 120 % Kurspotenzial

GBC Research hat mit der Coverage der Cryptology Asset Group PLC (ISIN: MT0001770107) begonnen. Die Bewertung der führenden europäischen Investmentgesellschaft für Krypto-Assets und Blockchain-Unternehmen erfolgte mittels der Berechnung des Net Asset Value (NAV). Unter Berücksichtigung aller Beteiligungen ergibt sich zum 05. Juli 2021 eine GBC-Fair-NAV-Bewertung in Höhe von 1,04 Mrd. EUR. Daraus ergibt sich ein NAV je Cryptology-Aktie von 358,43 EUR. Daher empfiehlt GBC Research die Cryptology-Aktie zum Kauf und sieht ein Kurspotenzial von über 120 %.

News im Fokus

Starkes Reifengeschäft im zweiten Quartal: Continental mit respektablem Ergebnis

05. August 2021, 08:30

Aktueller Webcast

HelloFresh SE

Q2 2020 Results Webcast

10. August 2021

Aktuelle Research-Studie

Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index

04. August 2021